PDF herunterladen
Horm Metab Res 1992; 24(7): 329-332
DOI: 10.1055/s-2007-1003325
Clinical

© Georg Thieme Verlag, Stuttgart · New York

The Effect of the Somatostatin Analogue Octreotide on Growth Hormone Secretion in Insulin-Dependent Diabetics Without Residual Insulin Secretion

M. I. Wurzburger, G. M. Prelevic, P. H. Sonksen, L. A. Balint-Peric
  • Endocrinology Department, University Medical Centre “Zvezdara”, Belgrade, Yugoslavia, and Department of Medicine, United Medical and Dental Schools of Guy's and St. Thomas' Hospital, St. Thomas' Hospital, London, United Kingdom
Weitere Informationen

Publikationsverlauf

1991

1991

Publikationsdatum:
14. März 2008 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Growth hormone (GH) hypersecretion is well documented in insulin-dependent diabetes mellitus (IDDM). Somatostatin inhibits GH in acromegalics and healthy subjects although data on its inhibitory effects on high GH levels in IDDM patients are controversial.

The effect of treatment with the Somatostatin analogue octreotide (“Sandostatin”) on GH secretion, IGF1 levels and metabolic control was investigated in insulin-dependent diabetics.

Growth hormone and blood glucose were measured at hourly intervals whilst IGF-I was measured every 6 hours during the 24-h period before and after 7 days' treatment with octreotide (200 μg subcutaneously three times daily) in 10 C-peptide negative diabetics.

Octreotide significantly reduced mean 24 h GH profile (7.2±0.7 mU/L before; 5.2±0.5 mU/L on octreotide, p < 0.01), IGF-I levels (0.62±0.06 before; 0.47±0.05 on octreotide, p < 0.005) mean 24 h blood glucose (14.4±0.5 mmol/L before; 12.6±0.4 mmol/L on octreotide, p < 0.001) and daily insulin requirements (44.8±3.0 IU before; 37.2±3.0 IU on octreotide, p < 0.02). The shape of 24 h GH profile curve changed significantly on octreotide treatment (p < 0.05) when it consisted of three nadirs and three peaks closely linked with the time of octreotide administration.

Moderate (abdominal discomfort) to severe (hypoglycaemia) transient side effects have been observed in all treated patients.

The results of this study showed that short-term treatment with octreotide given s. c. every eight hours modulates the pattern of GH secretion in C-peptide negative insulin-dependent patients. We hypothesize that these changes are the result of a dual effect of octreotide on pituitary somatotropes (inhibitory and priming) and possibly also, altered pharmacokinetics of octreotide in insulin-dependent diabetics.

Key words

Insulin-Dependent Diabetes Mellitus - Residual Beta Cell Function - Growth Hormone - Blood Glucose - Octreotide